CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML

PURPOSE: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1(T315I)-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1(T315I)-mutated CML remains a clinical challenge. Hydroxyurea (HU) has been used for cytoreduction...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Schneeweiss-Gleixner, Mathias, Byrgazov, Konstantin, Stefanzl, Gabriele, Berger, Daniela, Eisenwort, Gregor, Lucini, Chantal Blanche, Herndlhofer, Susanne, Preuner, Sandra, Obrova, Klara, Pusic, Petra, Witzeneder, Nadine, Greiner, Georg, Hoermann, Gregor, Sperr, Wolfgang R., Lion, Thomas, Deininger, Michael, Valent, Peter, Gleixner, Karoline V.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6921367/
https://ncbi.nlm.nih.gov/pubmed/31761618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados